REFERENCES
- Jager E, van der Velden VH, te Marvelde JG, Walter RB, Agur Z, Vainstein V. Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS ONE. 2011;6:e24265.
- Kuypers DR. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients. Clin Pharmacol Ther. 2010;88:595–596.
- Nath CE, McLachlan AJ, Shaw PJ, Coakley JC, Earl JW. Amphotericin B dose optimization in children with malignant diseases. Chemotherapy. 2007;53:142–147.
- Hammoud HA, Aymard G, Lechat P, Boccheciampe N, Riou B, Aubrun F. Relationships between plasma concentrations of morphine, morphine-3-glucuronide, morphine-6-glucuronide, and intravenous morphine titration outcomes in the postoperative period. Fund Clin Pharmacol. 2011;25:518–527.
- Available at: http://www.medicine.ox.ac.uk/bandolier/booth/ Palliative/Mometab.html. Last accessed February 17, 2013.
- Hammoud HA, Simon N, Urien S, Riou B, Lechat P, Aubrun F. Intravenous morphine titration in immediate postoperative pain management: population kinetic-pharmacodynamic and logistic regression analysis. Pain. 2009;144:139–146.
- Mazoit JX, Butscher K, Samii K. Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. Anesth Analg. 2007;105:70–78.
- Murthy BR, Pollack GM, Brouwer KL. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol. 2002;42:569–576.
- Lotsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med. 2005;11:82–89.
- Wittwer E, Kern S.E. Role of morphine's metabolites in analgesia: concepts and ontroversies. AAPS J. 2006;8: E348–E352.
- Portenoy RK, Thaler HT, Inturrisi CE, Friedlander-Klar H, Foley KM. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther. 1992;51:422–431.
- Skarke C, Geisslinger G, Lotsch J. Is morphine-3-glucuronide of therapeutic relevance? Pain. 2005;116:177–180.
- Pennson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML. Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther. 2000;68: 667–676.
- Mashayekhi SO, Sattari MR, Routledge PA. Evidence of active transport involvement in morphine transport via MDCKII and MDCK-PGP cell lines. Res Pharm Sci. 2010;5:99–106.
- Sam WJ, MacKey SC, Lötsch J, Drover DR. Morphine and its metabolites after patient-controlled analgesia: considerations for respiratory depression. J Clin Anesth. 2011;23:102–106.
- De Gregori S, De Gregori M, Ranzani GN, Allegri M, Minella C, Regazzi M. Morphine metabolism, transport and brain disposition. Metab Brain Dis. 2012;27:1–5.
- Hannam JA, Anderson BJ. Contribution of morphine and morphine-6-glucuronide to respiratory depression in a child. Anaesth Intensive Care. 2012;40:867–870.
- Martini C, Olofsen E, Yassen A, Aarts L, Dahan A. Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature. Expert Rev Clin Pharmacol. 2011;4:719–728.